Phase 4 N=148 GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study
Peripheral Vascular Diseases
Primary: Efficacy: Primary Patency at Three Years — 24.2; 25.9 percentage of subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=57 Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project
Atherosclerosis of Native Arteries of the Extremities
Primary: Primary Patency — 94.4 percentage of lesions
N/A N=474 Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery
Peripheral Vascular Diseases
Primary: Event-free Survival Rate — 90.4; 83.9 Percentage of participants — p=<0.01
N/A N=82 TurboPower + DCB Treatment of Femoropopliteal De Novo/ Restenotic and In-Stent Restenosis Lesions
Peripheral Arterial Disease
Primary: Number of Participants Free From Target Lesion Revascularization (TLR) — 52 Participants
N/A N=196 The Complete® SE SFA Study for the Treatment of SFA/PPA Lesions
Peripheral Vascular Disease
Primary: Major Adverse Event (MAE) Rate — 11.0 percentage of participants
N/A N=287 Safety and Effectiveness Study of EverFlex Stent to Treat Symptomatic Femoral-popliteal Atherosclerosis
Peripheral Vascular Diseases · Claudication
Primary: Primary Patency — 67.7 Percentage of participants with data
N/A N=29 JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions
Restenosis · Peripheral Vascular Disease
Primary: Acute Procedural Success — 29 limbs
N/A N=528 ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent
Atherosclerosis of Native Arteries of the Extremities
Primary: Percentage of Participants With Major Adverse Events (MAEs) — 0; 0; 0; 0 percentage of participants — p=<0.0001
N/A N=141 Absolute Pro® MOMENTUM™
Peripheral Artery Disease · Peripheral Vascular Disease
Primary: Major Adverse Event (MAE) — 0.0; 0.0; 0.0 percentage of participants
N/A N=60 Evaluation of the GORE® VIABAHN® Endoprosthesis for the Treatment of Popliteal Artery Aneurysm (PAA)
Popliteal Artery Aneurysm
Primary: Number of Subjects With Primary Patency at 12 Months — 40; 11 Participants
N/A N=113 Treatment of Peripheral Arterial Hemorrhage With Lava LES (The LAVA Study)
Peripheral Arterial Hemorrhage
Primary: Percentage of Participants With Composite of Freedom From Major Adverse Events (MAEs) — 100 percentage of participants — p=<0.025
N/A N=76 CVT-SFA First in Human Trial for Treatment of Superficial Femoral Artery or Proximal Popliteal Artery
Femoral Artery Stenosis · Popliteal Artery Stenosis · Femoral Artery Occlusion
Primary: Number and Percentage of Participants With Freedom of Major Adverse Event (MAE) Rate — 72 Participants
N/A N=171 Multi-center Study for Stent Graft System for Peripheral Artery
Peripheral Arterial Disease
Primary: Primary Assisted Patency — 91 Participants — p=<0.0001
N/A N=78 DETOUR I Clinical Study for Percutaneous Femoropopliteal Bypass
Peripheral Arterial Disease
Primary: Number of Lesions With Primary Patency — 72 Lesions
N/A N=358 Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia
Critical Lower Limb Ischemia
Primary: Late Lumen Loss (LLL) of the Target Lesion by Quantitative Vascular Angiography (QVA) — 0.605; 0.616 mm
N/A N=112 Evaluation of the FreedomFlow™ Orbital Atherectomy System to Treat Peripheral Artery Disease
Peripheral Arterial Disease
Primary: Technical Success — 144 lesion
N/A N=294 ILLUMENATE EU Randomized Clinical Trial
Peripheral Arterial Disease · Claudication
Primary: Patency at 12-months — 83.9; 60.6 percentage of lesions
Phase 4 N=102 Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
Peripheral Arterial Disease
Primary: Effect of Intensive Lipid Modification Medication Therapy on Progression of Atherosclerosis and Restenosis of Femoral Arteries Measured Using High Resolution Magnetic…
N/A N=799 Study of SilverHawk®/TurboHawk® in Lower Extremity Vessels (DEFINITIVE™ LE)
Peripheral Arterial Disease · Claudication · Critical Limb Ischemia
Primary: Primary Patency Rate (in Patients Treated for Claudication RCC 1-3) — 81.6 percentage of lesions by Kaplan Meier
N/A N=25 Tissue Removal Assessment With Ultrasound of THe SFA and Popliteal
Peripheral Artery Disease · PAD · Claudication
Primary: Rate of Clinically Driven Target Lesion Revascularization (TLR) — 4.0; 8.2 % probablity of clinically driven TLR
Phase 4 N=840 Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
Peripheral Arterial Occlusive Disease
Primary: Complete Healing of Ischemic Necroses and Ulcerations at 12 Weeks After the End of Study Drug Treatment — 49; 43; 27; 30 participants — p=0.2587
N/A N=60 Directional Versus Orbital Atherectomy Plaque Modification and Luminal Area Assessment of the Femoro-popliteal Artery Via Intravascular Ultrasound
Peripheral Artery Disease
Primary: Change in Minimal Luminal Area — 5.8; 4 mm^2
N/A N=250 S.M.A.R.T.® Nitinol Self-Expandable Stent in the Treatment of Obstructive Superficial Femoral Artery Disease
Superficial Femoral Artery Disease
Primary: 12-month Primary Patency Rate — 143; 72 participants — p=0.437
N/A N=85 Comprehensive Magnetic Resonance of Peripheral Arterial Disease
Peripheral Artery Disease
Primary: Plaque Volume — 10.5; 10.5; 10.8 cm^3 — p=0.32
N/A N=32 PROMISE I Early Feasibility Trial of the LimFlow Stent Graft System
Critical Limb Ischemia · Chronic Limb-Threatening Ischemia
Primary: Amputation-free Survival — 90.6 Percentage of participants
N/A N=51 Complete Lesion Assessment With ffR and IVUS TechnologY
Peripheral Artery Disease · Critical Limb Ischemia
Primary: Percentage of Calcium Removal Out of Lumen Gain as Assessed by IVUS — 25.0; 0.0 percentage of lumen gain — p=0.0220
N/A N=82 Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis
Femoral Artery Stenosis · Femoral Artery Occlusion · Restenosis
Primary: Percentage of Participants With Primary Patency at 1 Year — 67.0; 49.5 Percentage of Participants
N/A N=72 Jetstream in Treatment of Occlusive Atherosclerotic Lesions in the SFA and/or PPA
Atherosclerosis
Primary: The Primary Effectiveness Endpoint-Acute Reduction of Percent Diameter Stenosis — 39.3; 42.8; 39.9 percentage of DS(diameter stenosis)
N/A N=264 Comparison of the SUpera® PERipheral System in the Superficial Femoral Artery
Peripheral Vascular Disease
Primary: Primary Safety Endpoint: Freedom From Death, Target Lesion Revascularization (TLR), or Any Amputation of the Index Limb to 30 (±7) Days. — 99.2; 99.6; 99.6; 100.0…
N/A N=45 Zilver PTX Drug-Eluting Peripheral Stent Study
Peripheral Arterial Disease
Primary: Percent Change in Stent Length Upon Deployment — 0.5; -0.2 Change in stent length (%) — p=<0.01